Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377276 | 0.87 | C5 (0.41) | EPHX2MAPK1LIPGHSD17B10MLNR | |
| SCHEMBL19377171 | 0.87 | HSD17B10 (0.42) | EPHX2MAPK1LIPGHSD17B10MLNR | |
| SCHEMBL19377008 | 0.87 | EPHX2 (0.41) | EPHX2MAPK1LIPGHSD17B10MLNR | |
| SCHEMBL19377541 | 0.86 | EPHX2 (0.38) | EPHX2MAPK1LIPGHSD17B10MLNR | |
| SCHEMBL19406962 | 0.86 | EPHX2 (0.38) | EPHX2MAPK1LIPGHSD17B10MLNR | |
| SCHEMBL19377041 | 0.86 | KMT2A (0.43) | EPHX2ITGB3ITGA2B | |
| SCHEMBL19377025 | 0.85 | EPHX2 (0.37) | EPHX2MAPK1LIPGHSD17B10MLNR | |
| SCHEMBL19377281 | 0.85 | ALDH1A1 (0.43) | EPHX2MAPK1LIPGHSD17B10MLNR | |
| SCHEMBL19377236 | 0.85 | MAPK1 (0.38) | EPHX2MAPK1LIPGHSD17B10MLNR | |
| SCHEMBL19377218 | 0.84 | HSD17B10 (0.49) | EPHX2HSD17B10MLNRGFERITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390355-B1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-12-28 | — | — | EP | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| EP-3390355-B1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-12-28 | — | — | EP | disclosed |
| EP-3390355-B1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-12-28 | — | — | EP | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | EPHX2 2879/4885MAPK1 4001/4885LIPG 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.